States Report Significant ACA Coverage Losses as Enhanced Subsidies Expire
Several states are experiencing major coverage losses under the Affordable Care Act as enhanced federal subsidies have not been renewed by Congress. Monthly enrollment data through April from six states shows substantial cancellations and unpaid premiums following 2026 sign-ups, according to Georgetown University analysis. The trend suggests the impact of subsidy expiration may be more severe than previously estimated.
Newly released state enrollment data indicate that ACA coverage losses could exceed initial projections, driven by Congress's failure to renew enhanced subsidies that had made insurance more affordable. Data from Arkansas, Colorado, Maryland, Massachusetts, New Mexico, and New York through April show significant numbers of people canceling coverage or failing to pay premiums after enrolling in 2026, according to an analysis from Georgetown University. The enhanced subsidies, which had temporarily reduced out-of-pocket costs for many enrollees, were a key factor in the ACA's improved enrollment numbers in recent years. Federal officials have released limited data on the broader national impact so far. The coverage losses raise questions about the sustainability of ACA enrollment without continued subsidy support.
What's missing
The article excerpt does not provide the specific numbers or percentages of coverage losses reported, the timeline for when enhanced subsidies expired, or details on federal officials' expected timeline for releasing comprehensive national data.
What different sources said
- The HillCenter
States starting to see major ObamaCare coverage losses
Related
Shaquille O'Neal Reveals Use of GLP-1 Drug Zepbound for Sleep Apnea and Weight Management
Shaquille O'Neal disclosed that he has been taking the GLP-1 drug Zepbound to address obstructive sleep apnea, a condition he was diagnosed with in 2011 after retiring from the NBA. GLP-1 medications were originally developed for Type 2 diabetes and sleep apnea but have gained popularity as weight-loss drugs among celebrities and athletes. O'Neal's disclosure adds to a growing trend of high-profile athletes publicly using these medications for health and wellness purposes.
San Diego Plastic Surgeon Ordered to Stop Practicing After Failing Alcohol Tests While on Probation
Dr. Abhay Gupta, a San Diego-area plastic surgeon, has been ordered to cease practicing after testing positive for alcohol three times within 10 days while under probation conditions. Gupta's medical license was revoked in 2022 following a 2019 DUI conviction, but he was allowed to continue operating under strict conditions including alcohol abstinence and regular testing. Patient advocates are raising concerns about how many patients may have been affected during the years of disciplinary actions.
Employers Face 'Prisoner's Dilemma' Over GLP-1 Coverage Decisions
Pharmaceutical and benefits industry leaders discussed at a Newsweek webinar why only 36% of employers cover GLP-1 therapies despite evidence that obesity costs the U.S. healthcare system over $261 billion annually. The debate centers on a 'prisoner's dilemma' where individual employers hesitate to invest in treatments whose financial returns may take years to materialize, even though not covering them carries significant long-term costs. The discussion highlights how GLP-1 coverage decisions could affect workforce retention and talent recruitment, particularly among younger employees.